Figshare
open access
CC BY 4.0
Supplemental Material for: Drug persistence and treatment outcomes after switching from intravenous to subcutaneous vedolizumab in inflammatory bowel disease
Introduction: Subcutaneous (SC) vedolizumab (VDZ) offers an alternative to intravenous (IV) administration for maintenance therapy in inflammatory bowel disease (IBD); however, long-term real-world evidence after IV-to-SCtransition remains limited. This study evaluated long-term effecti
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis#1093621
- A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)#1102147
- Efficacy and Safety of Vedolizumab in Biologic-naïve Korean Patients With Moderate to Severe Inflammatory Bowel Disease#908287
- Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)#1149925
- Open-label Extension Study of Brazikumab in Ulcerative Colitis#845767
Record · ID 1052888
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive